Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
- Wednesday, January 29, 2020, 7:01
- Finance
- Add a comment
INDIANAPOLIS, Jan. 29, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the treatment of patients with advanced RET…
About the Author
adminasapcorp has written 41532 stories on this site.